Introduction: While current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows disease progression, prognosis remains poor. Therefore, an unmet need exists for novel, well-tolerated agents that reduce lung function decline and improve quality of life. Here we report the design of two phase III studies of the novel IPF therapy, GLPG1690. Methods and analysis: Two identically designed, phase III, international, randomised, double-blind, placebo-controlled, parallel-group, multicentre studies (ISABELA 1 and 2) were initiated in November 2018. It is planned that, in each study, 750 subjects with IPF will be randomised 1:1:1 to receive oral GLPG1690 600 mg, GLPG1690 200 mg or placebo, once daily, on top of local SOC, for at lea...
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has been ...
Huzaifa I Adamali,1 Toby M Maher1–31Interstitial Lung Disease Unit, Royal Brompton Hospita...
Idiopathic pulmonary fibrosis (IPF) is a progressivediseasewithamediansurvivalof 3–5 years (1, 2). Th...
Introduction While current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows dis...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. People wi...
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with increasing incidence; th...
SummaryBackgroundNintedanib is in clinical development as a treatment for idiopathic pulmonary fibro...
Background: TAS-115, a novel multi-kinase inhibitor, demonstrated antifibrotic effects in vitro and ...
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is an age-related disease of unknown cause. The di...
International audienceRationale: An efficacious medical therapy for idiopathic pulmonary fibrosis (I...
International audienceBACKGROUND & nbsp;Phosphodiesterase 4 (PDE4) inhibition is associated with ant...
Background: Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of f...
Introduction: Idiopathic pulmonary fibrosis (IPF) is a challenging and multifactorial disease that h...
Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF...
Background: Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of f...
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has been ...
Huzaifa I Adamali,1 Toby M Maher1–31Interstitial Lung Disease Unit, Royal Brompton Hospita...
Idiopathic pulmonary fibrosis (IPF) is a progressivediseasewithamediansurvivalof 3–5 years (1, 2). Th...
Introduction While current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows dis...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. People wi...
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with increasing incidence; th...
SummaryBackgroundNintedanib is in clinical development as a treatment for idiopathic pulmonary fibro...
Background: TAS-115, a novel multi-kinase inhibitor, demonstrated antifibrotic effects in vitro and ...
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is an age-related disease of unknown cause. The di...
International audienceRationale: An efficacious medical therapy for idiopathic pulmonary fibrosis (I...
International audienceBACKGROUND & nbsp;Phosphodiesterase 4 (PDE4) inhibition is associated with ant...
Background: Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of f...
Introduction: Idiopathic pulmonary fibrosis (IPF) is a challenging and multifactorial disease that h...
Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF...
Background: Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of f...
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has been ...
Huzaifa I Adamali,1 Toby M Maher1–31Interstitial Lung Disease Unit, Royal Brompton Hospita...
Idiopathic pulmonary fibrosis (IPF) is a progressivediseasewithamediansurvivalof 3–5 years (1, 2). Th...